Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/32901
Title: Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study
Authors: STESSEL, Bjorn 
Vancuchelen, Charlotte
BRUCKERS, Liesbeth 
Geebelen, Laurien
CALLEBAUT, Ina 
VANDENBRANDE, Jeroen 
Pallens, Ben
Van Tornout, Michiel
Ory, Jean-Paul
van Halem, Karlijn
MESSIAEN, Peter 
HERBOTS, Lieven 
Ramaekers, Dirk
Dubois, Jasperina
Issue Date: 2020
Publisher: PERGAMON-ELSEVIER SCIENCE LTD
Source: THROMBOSIS RESEARCH, 194 , p. 209 -215
Abstract: Introduction: An individualised thromboprophylaxis was implemented in critically ill patients suffering from coronavirus disease 2019 (COVID-19) pneumonia to reduce mortality and improve clinical outcome. The aim of this study was to evaluate the effect of this intervention on clinical outcome. Methods: In this mono-centric, controlled, before-after study, all consecutive adult patients with confirmed COVID-19 pneumonia admitted to ICU from March 13th to April 20th 2020 were included. A thromboprophylaxis protocol, including augmented LMWH dosing, individually tailored with anti-Xa measurements and twice-weekly ultrasonography screening for DVT, was implemented on March 31th 2020. Primary endpoint is one-month mortality. Secondary outcomes include two-week and three-week mortality, the incidence of VTE, acute kidney injury and continuous renal replacement therapy (CRRT). Multiple regression modelling was used to correct for differences between the two groups. Results: 46 patients were included in the before group, 26 patients in the after group. One month mortality decreased from 39.13% to 3.85% (p < 0.001). After correction for confounding variables, one-month mortality was significantly higher in the before group (p = 0.02, OR 8.86 (1.46, 53.75)). The cumulative incidence of VTE and CRRT was respectively 41% and 30.4% in the before group and dropped to 15% (p = 0.03) and 3.8% (p = 0.01), respectively. After correction for confounding variables, risk of VTE (p = 0.03, 6.01 (1.13, 32.12)) and CRRT (p = 0.02, OR 19.21 (1.44, 255.86)) remained significantly higher in the before group. Conclusion: Mortality, cumulative risk of VTE and need for CRRT may be significantly reduced in COVID-19 patients by implementation of a more aggressive thromboprophylaxis protocol. Future research should focus on confirmation of these results in a randomized design and on uncovering the mechanisms underlying these observations. .
Notes: Stessel, B (corresponding author), Jessa Hosp Hasselt, Dept Intens Care & Anesthesiol, Virga Jesse Campus,Stadsomvaart 11, B-3500 Hasselt, Belgium.
bjorn.stessel@jessazh.be
Other: Stessel, B (corresponding author), Jessa Hosp Hasselt, Dept Intens Care & Anesthesiol, Virga Jesse Campus,Stadsomvaart 11, B-3500 Hasselt, Belgium. bjorn.stessel@jessazh.be
Keywords: COVID-19;Thromboprophylaxis;Venous thromboembolism;Mortality;Continuous renal replacement therapy
Document URI: http://hdl.handle.net/1942/32901
ISSN: 0049-3848
e-ISSN: 1879-2472
DOI: 10.1016/j.thromres.2020.07.038
ISI #: WOS:000568490100037
Category: A1
Type: Journal Contribution
Validations: ecoom 2021
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
1-s2.0-S0049384820303297-main.pdfPublished version558.17 kBAdobe PDFView/Open
Show full item record

WEB OF SCIENCETM
Citations

34
checked on Oct 14, 2024

Page view(s)

34
checked on Jun 14, 2022

Download(s)

32
checked on Jun 14, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.